SYMBIONT Bio is a spin-out from the Buck Institute for Research on Aging (The Buck), the first independent research facility solely dedicated to studying aging and age-related diseases.

During the past 20 years at the Buck, Symbiont’s renown researchers and founders have been studying ways to understand the mitochondria, modulate mitophagy and understand its impact on disease and aging.

With over $20M in funding for mitochondrial research alone, over $50M in overall funding and over 300 publications in top-tier journals, they have identified novel compounds that are strong Mitophagy Inducing Compounds (MIC) which may have a significant role on disease and aging.

The comprehensive results of this research led to the establishment of Symbiont Bio in July of 2023.

Buck Institute for Research on Aging

The Buck focuses its efforts on understanding the biological mechanisms underlying aging processes and age-related diseases such as Alzheimer’s, Parkinson’s, cancer, and cardiovascular diseases. Their research spans a wide range of topics, including genetics, cell biology, metabolism, and neurobiology, all with the aim of uncovering the fundamental processes that contribute to aging and age-related conditions.

We identified novel compounds that are strong Mitophagy Inducing Compounds (MIC)

These compounds may have a significant role on disease and aging.